Paradigm Biocapital Advisors’s Tarsus Pharmaceuticals TARS Stock Holding History

Paradigm Biocapital Advisors’s Portfolio TARS Stock Details TARS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$175M	Buy	2,775,649 +213,495	+8%	+$13.6M	3.27%	11
2026 Q1	$180M	Hold	2,562,154	–	–	3.67%	8
2025 Q4	$210M	Sell	2,562,154 -103,544	-4%	-$7.73M	5.35%	5
2025 Q3	$158M	Sell	2,665,698 -310,401	-10%	-$15.3M	4.51%	5
2025 Q2	$121M	Buy	2,976,099 +365,902	+14%	+$16.5M	5.15%	5
2025 Q1	$134M	Buy	2,610,197 +78,301	+3%	+$3.87M	6.14%	6
2024 Q4	$140M	Buy	2,531,896 +91,451	+4%	+$4.15M	4.88%	6
2024 Q3	$80.3M	Buy	2,440,445 +5,029	+0.2%	+$141K	2.72%	9
2024 Q2	$66.2M	Sell	2,435,416 -427,990	-15%	-$14.4M	2.53%	14
2024 Q1	$104M	Buy	2,863,406 +1,838,406	+179%	+$54.1M	3.66%	11
2023 Q4	$20.8M	Buy	+1,025,000	New	+$17.1M	0.97%	22

Other funds holding TARS

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Paradigm Biocapital Advisors's TARS Position: Q2 2026 in Review

Paradigm Biocapital Advisors increased its Tarsus Pharmaceuticals (TARS) stake by 8.3% in Q2 2026, buying an estimated $13.6M and bringing the position to 2,775,649 shares worth $175M. The position accounts for 3.27% of the portfolio, ranked #11.

Paradigm Biocapital Advisors first reported a position in TARS in Q4 2023 and has held it in 11 quarters since. The position peaked at $210M in Q4 2025. 257 funds tracked by Wall St. Rank hold TARS as of Q2 2026.

Paradigm Biocapital Advisors held 2,775,649 shares of Tarsus Pharmaceuticals worth $175M as of Q2 2026.
Paradigm Biocapital Advisors bought 213,495 Tarsus Pharmaceuticals shares in Q2 2026, an estimated $13.6M.
Tarsus Pharmaceuticals made up 3.27% of Paradigm Biocapital Advisors's portfolio in Q2 2026, its #11 holding.
Paradigm Biocapital Advisors first reported a position in Tarsus Pharmaceuticals in Q4 2023 and has held it in 11 quarters since.
Paradigm Biocapital Advisors's Tarsus Pharmaceuticals position peaked at $210M in Q4 2025.
257 funds tracked by Wall St. Rank held Tarsus Pharmaceuticals as of Q2 2026.

Based on Paradigm Biocapital Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.